Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of Aarhus |
---|---|
Information provided by: | University of Aarhus |
ClinicalTrials.gov Identifier: | NCT00435175 |
Estradiol promotes and maintains the typical female phenotype characterized by subcutaneous fat accumulation. There is evidence to suggest that this effect relies on the ability of estradiol to increase the amount of anti-lipolytic α2A-adrenergic receptors, but whether this requires long-term exposure to estradiol or is the result of an immediate effect is not clear. Objective: To study acute effects of a single dose (4 mg) of 17β-estradiol on regional and systemic lipolysis.
Condition | Intervention |
---|---|
Postmenopause |
Drug: estradiol |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Placebo Control, Crossover Assignment, Pharmacodynamics Study |
Official Title: | Acute Effects of Estradiol on Lipolysis in Subcutaneous Adipose Tissue and Muscle Assessed by Microdialysis and Tissue Biopsies |
Estimated Enrollment: | 8 |
Study Start Date: | June 2005 |
Estimated Study Completion Date: | July 2006 |
Estradiol affects muscle and fat distribution, and thereby lipid metabolism. A reduction in muscle power is seen after menopause, readily counteracted by female hormone therapy (HT). Treatment with HT through months to previously untreated postmenopausal women, or hormone replacement therapy (HRT) to women with Turner syndrome, increases muscle mass and reduces fat mass. HT in postmenopausal women furthermore prevents fat accumulation and increases lipoprotein lipase activity and lipolysis to an extent comparable to premenopausal women. In contrast, it has also been shown that estradiol may actually attenuate lipolysis during basal as well as catecholamine stimulated conditions. In addition, one study found whole body fat metabolism to be lower during treatment with estradiol than without, and reduced lipolysis is present in postmenopausal women during treatment with estradiol, along with an increased number of α-adrenergic receptors and a decreased number of β-adrenergic receptors.
It is not clear whether the lipolytic effect of estradiol happens acutely or is dependent on chronic exposure. Moreover, regional differences in the pharmacodynamics of estradiol have not been assessed. Finally, effects on skeletal muscle have never been examined.
The purpose of the present study was 1) by microdialysis to quantify the regional production of glycerol in two tissues (muscle and fat), and in two regions (abdominal and femoral). 2) To quantify the whole-body lipolytic effect of estradiol, and 3) in biopsies to study intracellular mechanisms behind the action of estradiol.
Ages Eligible for Study: | 45 Years to 70 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 2002-0242 |
Study First Received: | February 13, 2007 |
Last Updated: | February 13, 2007 |
ClinicalTrials.gov Identifier: | NCT00435175 |
Health Authority: | Denmark: Ethics Committee |
Estradiol Lipolysis Estrogen receptor |
Adrenergic receptors UCP2 Postmenopausal women |
Benzoates Estradiol 3-benzoate Estradiol valerate |
Estradiol 17 beta-cypionate Polyestradiol phosphate Estradiol |
Estrogens Contraceptive Agents Therapeutic Uses Physiological Effects of Drugs Contraceptive Agents, Female |
Hormones, Hormone Substitutes, and Hormone Antagonists Reproductive Control Agents Hormones Pharmacologic Actions |